15-Feb-2018 - Charles River Laboratories, Inc.

Charles River to Acquire MPI Research

Charles River announced that it has entered into a definitive agreement to acquire MPI Research for approximately $800 million in cash, subject to customary closing adjustments.

MPI is a premier non-clinical contract research organization (CRO) providing comprehensive testing services to biopharmaceutical and medical device companies worldwide. Acquiring MPI will enhance Charles River’s position as a leading global early-stage CRO by strengthening its ability to partner with clients across the drug discovery and development continuum.

James C. Foster, Chairman and Chief Executive Officer of Charles River Laboratories, commented, “In addition to meeting our disciplined acquisition criteria, MPI is an exceptional strategic fit for Charles River because it incorporates the key attributes we require in an acquisition: access to growing end markets, high-quality services, scientific expertise, and complementary capabilities. MPI’s one-million-square-foot, single-site facility in Michigan will provide needed capacity to meet current and future demand.”

Facts, background information, dossiers
  • Charles River
  • contract research o…
  • acquisitions
More about Charles River
  • News

    Charles River Laboratories Acquires Distributed Bio

    Charles River Laboratories International, Inc. announced that it acquired of Distributed Bio, Inc. on December 31, 2020. The acquisition marks the culmination of an exclusive partnership between these companies that was initiated in October 2018. Based in South San Francisco, California, Di ... more

    Charles River to Acquire HemaCare

    Charles River Laboratories International, Inc. and HemaCare Corporation announced a definitive agreement for Charles River to acquire HemaCare for approximately $380 million in cash. HemaCare is a leader in the production of human-derived cellular products for the cell therapy market. The b ... more

    Charles River Laboratories to acquire French CRO

    Charles River Laboratories International, Inc. announced that it has signed a binding offer to acquire Citoxlab for €448 million in cash (or approximately $510 million based on current exchange rates), subject to customary closing adjustments. The proposed transaction is expected to close i ... more

  • Companies

    Charles River Endotoxin Microbial Detection Europe SAS

    Charles River is the world's leading supplier of endotoxin detection products. As a global provider of rapid microbiological product solutions, our goal is to provide superior product quality and consistency to the scientific community. more

    Charles River Laboratories, Inc.

    From our headquarters near Boston, MA, Charles River Laboratories' 7,500 employees serve clients as global providers of solutions that advance the drug discovery and development process. Our leading-edge products and services enable our clients to bring drugs to market faster and more eff ... more

    Charles River Laboratories Clinical Services GmbH

    From our headquarters near Boston, MA, Charles River Laboratories' 7,500 employees serve clients as global providers of solutions that advance the drug discovery and development process. Our leading-edge products and services enable our clients to bring drugs to market faster and more eff ... more